$XBI $122.22 -0.58%
Pipeline Updates
$ASND -4.1% Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparathyroidism source
$MRKR -7.4% MARKER THERAPEUTICS ANNOUNCES THAT DATA FROM INVESTIGATOR-SPONSORED PHASE 1 STUDY WITH ITS MULTITAA-SPECIFIC T CELLS TO BE PRESENTED AT THE 2021 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING source
$CNTB -1.2% Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis source
$IMUX -6.0% Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis source
$ENTA +0.4% ENANTA PHARMACEUTICALS ANNOUNCES UPDATE TO ITS HEPATITIS B VIRUS (HBV) PROGRAM source
$IONS -1.0% Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema source
$SAVA +2.9% Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease source
$PSTV -4.2% PLUS THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM RESPECT™-GBM PHASE 1 CLINICAL TRIAL AT THE 2021 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING source
$LGVN +135.3% U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition source
$MTEM -5.1% Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402 source
$HRTX -2.0% Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA source
$VRCA -4.8% Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma source
$MRNA +3.8% Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV) Vaccine source
$FOLD -1.5% The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease source
$ORTX -3.3% Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome source
Business Updates
$OPTN -10.3% Optinose Announces Closing of $46.0 Million Public Offering of Common Stock source
$CBAY -1.7% CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants source
$DRNA +78.7% Novo Nordisk to Acquire Dicerna source
Posted by JM
Comments